Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
National Cancer Institute (NCI)
University of Nebraska
National Cancer Institute (NCI)
Institut Paoli-Calmettes
AstraZeneca
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Nkarta, Inc.
Hoffmann-La Roche
Eli Lilly and Company
BeOne Medicines
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Lyell Immunopharma, Inc.
Aurigene Discovery Technologies Limited
Eli Lilly and Company
Eli Lilly and Company
Curis, Inc.
University of Texas Southwestern Medical Center
Thomas Jefferson University
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Roswell Park Cancer Institute
AIDS Malignancy Consortium
Canadian Cancer Trials Group
Innate Pharma
Bristol-Myers Squibb
Verismo Therapeutics
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Merck Sharp & Dohme LLC
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Grifols Therapeutics LLC
Janssen Research & Development, LLC
Baylor College of Medicine
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
University of Pittsburgh
Janssen Research & Development, LLC